NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
23/05/2023
Voltar para busca
Dado oficial do USPTO
VICORE ALMEE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
VICORE ALMEE
ST13
US500000097123429Classe
9, 41, 42, 44
Pedido
97123429
Registro
7058751
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
23
Atualização mais recente
23/05/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
9, 41, 42, 44
Data de depósito
12/11/2021
Data de registro
23/05/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/05/2023
Última transação
23/05/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Gothenburg, SE
Examinador
RILEY, KATHERINE M
Unidade examinadora
M80
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Vicore Pharma AB
Representantes
Sarah J. Schneider SHERIDAN ROSS P.C.
Classificação técnica
Classes Nice
Classe 9Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Downloadable computer software with medical information and content for facilitating the provision of medical advice in the field of depression and anxiety related to Pulmonary Fibrosis; downloadable computer software programs for the administration of scientific content in the nature of analysis of medical data; downloadable computer programsin particular interactive downloadable medical software for treating patients suffering from depression and anxiety related to Pulmonary Fibrosis; downloadable computer software program which is designed to assist patients in reducing and coping with the symptoms of depression and anxiety related to Pulmonary Fibrosis as well as in improving their wellbeing and social occupational functioning and to support health care professionals involved in the treatment of patients with depression and anxiety related to Pulmonary Fibrosis by facilitating the provision of medical advice; downloadable computer application software for websitesmobile telephones and mobile devicessoftware for treating patients suffering from depression and anxiety related to Pulmonary Fibrosis; Downloadable printable educational materials featuring therapeutic medical and counseling contentin the nature of informationformsinstructionschartsstudiesdata and related coaching and advice in the field of depression and anxiety related to Pulmonary Fibrosistreatment of depression and anxiety related to Pulmonary Fibrosisrelated health and wellness; Downloadable electronic publicationsnewsletters and articles for use by medical professionals and patients in the field of depression and anxiety related to Pulmonary Fibrosis
Classe 41
Providing of on-line training and continuing education in the nature of virtual lectures in the field of medicinehealth and wellness for users in the medical fields with the aid of software; Educational servicesproviding continuing professional education courseswebinarsseminarsworkshops in the field of medicinehealth and wellness for patients suffering from depression and anxiety related to Pulmonary Fibrosis and for medical personnel specialized on the treatment of depression and anxiety
Classe 42
Providing a website featuring digital therapeutic technology that enables users to access resources for treating depression and anxiety related to Pulmonary Fibrosis; providing an online digital therapeutic platform in the nature of providing on-line non-downloadable software for providing behavioral health servicescoachingcounselingadvice in the field of depression and anxiety related to Pulmonary Fibrosis; conducting medical and scientific and technological research in the field of depression and anxiety related to Pulmonary Fibrosis; Scientific and technological servicesconducting technological research and design of digital therapeutics for computer-based interactive and online psychological intervention and counseling in the field of depression and anxiety related to Pulmonary Fibrosis; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of depression and anxiety related to Pulmonary Fibrosis and the treatment of depression and anxiety related to Pulmonary Fibrosis
Classe 44
Therapeutic servicesmedical counsellingpsychological counsellingmedical advice and medical information provided to patients withcare givers treatingdepression and anxiety related to Pulmonary Fibrosis; Providing medical informationcomputer-based interactive medical support servicesin the nature of providing online medical advice for assisting with treatment of patients suffering from depression and anxiety related to Pulmonary Fibrosis and their families; Medical treatment of depression and anxiety by medical personnel
Publicações
Histórico de despachos e eventos da marca no USPTO.
23 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
23/05/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/03/2023
PUBO
PUBLISHED FOR OPPOSITION
07/03/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/02/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/02/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
01/02/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/02/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
01/02/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/02/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
19/01/2023
GNRT
NON-FINAL ACTION E-MAILED
19/01/2023
CNRT
NON-FINAL ACTION WRITTEN
19/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/01/2023
ALIE
ASSIGNED TO LIE
06/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/11/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/09/2022
GNRT
NON-FINAL ACTION E-MAILED
02/09/2022
CNRT
NON-FINAL ACTION WRITTEN
02/09/2022
DOCK
ASSIGNED TO EXAMINER
23/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/11/2021
NWAP
NEW APPLICATION ENTERED
16/11/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VICORE ALMEE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.